Prime Medicine reported second quarter 2026 financial results with a net loss of $42.1 million and cash reserves of $108.8 million as of June 30, 2026. The company announced favorable arbitration resolution with Beam Therapeutics affirming its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with IND/CTA submission expected in Q3 2026. FDA cleared the IND and CTA for PM577a in Wilson disease, establishing a global Phase 1/2 program with initial data anticipated in 2027. The FDA also granted Regenerative Medicine Advanced Therapy designation to PM359 for chronic granulomatous disease, supporting a planned BLA submission in H1 2027. Prime Medicine operates as a biotechnology company developing gene editing therapies.

Prime Medicine, Inc. received a final arbitration award on July 6, 2026, ruling that its PM647 candidate for Alpha-1 Antitrypsin Deficiency treatment is within its defined field of use, meaning the company did not breach its 2019 Collaboration and License Agreement with Beam Therapeutics, Inc. The Tribunal denied all requests for damages and injunctive relief from Beam. Prime Medicine, Inc. is a biotechnology company focused on on-target genome editing.</u>

Prime Medicine, Inc. held its 2026 annual meeting of stockholders on June 5, 2026. Stockholders elected Michael Kelly and David Schenkein, M.D. as Class I Directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm.